Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4901
Lufax Holding
LU
$884M
| $1.26K | ﹤0.01% |
450
| – | – |
2022 Q1
13 quarters
|
|
4902
KLX Energy Services
KLXE
$29.5M
| $1.25K | ﹤0.01% |
667
-54
| -7% | -$112 |
2023 Q1
9 quarters
|
|
4903
CrossAmerica Partners
CAPL
$831M
| $1.21K | ﹤0.01% |
+58
| New | +$1.3K |
2025 Q2
0 quarters
|
|
4904
Senti Biosciences Holdings
SNTI
$10M
| $1.2K | ﹤0.01% |
569
+539
| +1,797% | +$1.71K |
2024 Q3
3 quarters
|
|
4905
PLDT
PHI
$3.79B
| $1.18K | ﹤0.01% |
54
| – | – |
2021 Q4
14 quarters
|
|
|
RDFN
4906
PUT
DELISTED
Redfin
RDFN
| $1.12K | ﹤0.01% |
+100
| New | +$981 |
2025 Q2
0 quarters
|
|
4907
iShares ESG Aware MSCI USA ETF
ESGU
$18.2B
| $1.08K | ﹤0.01% |
8
| – | – |
2023 Q1
9 quarters
|
|
4908
System1
SST
$21.2M
| $1.05K | ﹤0.01% |
190
-2,990
| -94% | -$13.3K |
2023 Q2
8 quarters
|
|
|
VLRS
4909
Controladora Vuela Compania de Aviacion
VLRS
$746M
| $1.04K | ﹤0.01% |
+220
| New | +$985 |
2025 Q2
0 quarters
|
|
|
THTX
4910
DELISTED
Theratechnologies
THTX
| $944 | ﹤0.01% |
+400
| New | +$980 |
2025 Q2
0 quarters
|
|
|
HLVX
4911
DELISTED
HilleVax
HLVX
| $894 | ﹤0.01% |
449
-31,670
| -99% | -$57.9K |
2022 Q2
12 quarters
|
|
|
BRAG
4912
Bragg Gaming Group
BRAG
$37.3M
| $864 | ﹤0.01% |
200
| – | – |
2022 Q3
11 quarters
|
|
|
JFIN
4913
Jiayin Group
JFIN
$69.6M
| $769 | ﹤0.01% |
48
-271,077
| -100% | -$3.68M |
2025 Q1
1 quarter
|
|
|
RPTX
4914
DELISTED
Repare Therapeutics
RPTX
| $737 | ﹤0.01% |
530
-75
| -12% | -$98 |
2023 Q2
8 quarters
|
|
4915
ProShares Bitcoin Strategy ETF
BITO
$1.73B
| $710 | ﹤0.01% |
33
-37
| -53% | -$763 |
2022 Q1
13 quarters
|
|
|
NA
4916
Nano Labs
NA
$48.4M
| $705 | ﹤0.01% |
76
| – | – |
2023 Q3
7 quarters
|
|
4917
Greystone Housing Impact Investors LP
GHI
$130M
| $645 | ﹤0.01% |
57
+48
| +533% | +$562 |
2024 Q4
2 quarters
|
|
4918
Telesat
TSAT
$731M
| $611 | ﹤0.01% |
25
| – | – |
2022 Q1
13 quarters
|
|
|
ADAP
4919
DELISTED
Adaptimmune Therapeutics
ADAP
| $608 | ﹤0.01% |
2,534
-47,534
| -95% | -$12.7K |
2023 Q2
8 quarters
|
|
|
EPIX
4920
DELISTED
ESSA Pharma
EPIX
| $604 | ﹤0.01% |
355
| – | – |
2024 Q3
3 quarters
|
|
|
IPHA
4921
Innate Pharma
IPHA
$178M
| $557 | ﹤0.01% |
307
| – | – |
2022 Q1
13 quarters
|
|
4922
Ebang International Holdings
EBON
$13.1M
| $531 | ﹤0.01% |
161
| – | – |
2023 Q3
7 quarters
|
|
4923
Equinor
EQNR
$101B
| $503 | ﹤0.01% |
+20
| New | +$484 |
2025 Q2
0 quarters
|
|
4924
Alaunos Therapeutics
TCRT
$2.08M
| $485 | ﹤0.01% |
100
-71
| -42% | -$214 |
2025 Q1
1 quarter
|
|
|
NUVB.WS
4925
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $442 | ﹤0.01% |
1,638
| – | – |
2022 Q1
13 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.